The Randomized Non-inferiority Trial of 19G and 22G FNB Needles in Pancreatic Tumor (19GFNB)

A Randomized Non-inferiority Trial Comparing 19G and 22G Needles in EUS-FNB Considering Comprehensive Genomic Profiling for Pancreatic Tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1042240023

Enrollment

100

Registered

2024-05-08

Start date

2024-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Endoscopic ultrasound-guided fine needle biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients suspected of pancreatic cancer based on image findings, determined to be either unresectable or borderline resectable. (2) Patients undergoing tissue sampling through EUS-FNB.

Exclusion criteria

Exclusion criteria: (1) History of previous radiotherapy or chemotherapy for pancreatic cancer. (2) Inability to temporarily discontinue anticoagulant therapy for EUS-FNB.

Design outcomes

Primary

Measure	Time frame
Technical success rate	—

Secondary

Measure	Time frame
Diagnostic accuracy Rate of adverse events Number of passes Length of macroscopic visible core Pathological score Rate of patients with passed or qualified from the reports of F1CDx Rate of patients with passed from the reports of F1CDx	—

Contacts

Public ContactHiroki Sakamoto

Shizuoka Cancer Center

h.sakamoto@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026